annual Report 2009 - STRATEC Biomedical AG

Report of the board of Management
Report of the supervisory board
THE share
Corporate Governance
Group Management report
Consolidated financial statements
Service
The following average useful lives have been applied for property, plant and equipment:
Useful life in years
Buildings 25 – 33
Outdoor facilities 10 – 15
Technical equipment and machinery 3 – 10
Vehicles 3 – 5
Tools 3 – 5
IT components 3 – 5
Other plant and office equipment 3 – 10
Company land in Germany is encumbered by land charges amounting to u 2,000 thousand (previous year: u 2,000 thousand)
provided as security for liabilities to banks. The company land abroad added in the 2009 financial year is encumbered
by land charges amounting to u 2,359 thousand provided as security for the construction costs of a company building
(CHF 3.5 million / u 2.36 million). The loan funds had not been drawn down as of 31 December 2009. The funds are
expected to be drawn down in line with the progress made with construction in the first half of 2010.
The development in property, plant and equipment from January 1 to December 31, 2009 has been presented in the
annex to the notes to the consolidated financial statements.
Financial assets
(3) Interests in associates
in v thousand 2009 2008
Carrying amount at 01.01. 284 337
Additions 10 8
Currency translation differences 16 -61
Carrying amount at 12.31. 310 284
Due to materiality considerations, STRATEC Biomedical Systems S.R.L., Romania, a wholly-owned subsidiary of Robion AG
founded in the previous year with share capital of RON 87,750.00 (u 25 thousand), continues not to be included in the
consolidated statements by way of full consolidation.
Interests in associates are presented in Section II “Principles of the consolidated financial statements / 2. Scope of consolidation”
and are classified pursuant to IAS 39 as “available for sale”. Unlisted equity instruments have been recognized
in the balance sheet at amortized group cost, as no stock market or other market price is available. Due to materiality
considerations, the Group has foregone measurement of these investments using the discounted cash flow method.
(4) Investments
The 13.42 % stake in the publicly listed company CyBio AG, Jena, reported at the previous year’s balance sheet date was
disposed of in full in the 2009 financial year. The resultant disposal gain of u 188 thousand has been recognized under
other financial income and expenses in the statement of comprehensive income.
stratec Annual Report 2009
71